COMPANY | Product/Compound | Mechanism | ARRANGEMENT |
Toray | REMITCH® (Narfurafine Hydrochloride) | K-opioid Receptor Agonist | In-License |
Gilead Sciences | Elvitegravir | Integrase Inhibitor | Out-License |
Novartis | Trametinib | MEK (MAPK/ERK Kinase) Inhibitor | Out-License |
Akebia | Riona® (Ferric Citrate) | Phosphate Binder Oral Iron Replacement(additional indication) | In-License |
ALK-Abello | Allergen Scratch Extract Positive Control (Torii) Histamine Dihydrochloride | Histamine Receptor Antagonist | In-License |
LEO Pharma | JTE-052 (delgocitinib) | JAK Inhibitor | Out-License |
JW Pharmaceutical | JTZ-951 (enarodustat) | HIF-PH Inhibitor | Out-License |
Rohto Pharmaceutical | JTE-052 (delgocitinib) | JAK Inhibitor | Out-License |
Shenzhen Salubris Pharmaceuticals | JTZ-951 (enarodustat) | HIF-PH Inhibitor | Out-License |
Dermavant Sciences GmbH | Tapinarof | Therapeutic AhR Modulating Agent | In-License |
BioCryst Pharmaceuticals | ORLADEYO Capsules | Plasma kallikrein inhibitor | In-License |
Nogra pharma | NAC-GED-0507 | Selective PPARγ modulator | In-License |
Verrica | VP-102 | 0.7% cantharidin | In-License |
Address
302 Carnegie Center, Suite 300
Princeton, NJ 08540
Office Hours
Mo-Fr: 8:00-19:00
Sa: 8:00-14:00
So: closed
Clinical Trial Privacy Notice
Contact
contact@akrospharma.com
Phone: 609-919-9570
Fax: 609-919-9575